Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics is a clinical-stage oncology biotech developing antibody-based therapies focused on angiogenesis and immune-oncology pathways. Its lead candidate, tovecimig (DLL4 x VEGF-A), met the study's primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone (p=0.031), and independent Data Monitoring Committee reviews recommended continuation. The company reports fewer overall survival events than modeled, with pooled OS analyses now expected in Q1 2026.
Financially, Compass recorded a net loss of $19.9 million for the quarter and $36.5 million for the six months, with an accumulated deficit of $401.2 million. Cash, cash equivalents and marketable securities totaled $101 million, which management expects will fund operations into 2027. Research and development expenses rose substantially, driven by increased manufacturing costs for tovecimig and CTX-10726, and the company reported accrued manufacturing obligations including $3.6 million minimum contractual commitments.
Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.